Trial Profile
The Effect of Afatinib on the Anti-Tumour Immune Response in Patients with Advanced Non-Small Cell Lung Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 21 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Dec 2013 New trial record